Gender-affirming hormone therapy in transgender women and risk of prostate cancer: pathophysiological mechanisms and clinical implications,Prostate Cancer and Prostatic Diseases

当前位置： X-MOL 学术 › Prostate Cancer Prostatic. Dis. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Gender-affirming hormone therapy in transgender women and risk of prostate cancer: pathophysiological mechanisms and clinical implications
Prostate Cancer and Prostatic Diseases ( IF 4.8 ) Pub Date : 2024-01-31 , DOI: 10.1038/s41391-024-00796-1
Eugenio Bologna , Leslie Claire Licari , Antonio Franco , Francesco Ditonno , Costantino Leonardo , Cosimo De Nunzio , Riccardo Autorino , Celeste Manfredi

Gender-affirming hormone therapy (GAHT) for transgender women (TGW) transition is typically based on a combination of estrogens and androgen deprivation therapy [1]. This treatment is designed to recalibrate the hormonal balance in TGW.

中文翻译：